Infantile hemangiomas are the most common tumors of infancy. 1 They typically appear in the first weeks of life in a rapid growth phase, proliferate over the course of 3-6 months, stabilize over a period of few months, and then spontaneously involute over several years, usually within 5-7 years. 1 Until recently, corticosteroids had been the first-line treatment for life-or function-threatening infantile hemangiomas, with other treatment options being vincristine and interferon alpha. [2] [3] [4] [5] [6] However, these therapies have multiple side effects, some of which are serious. [7] [8] [9] In a recent case series, 10 propranolol was used to treat the obstructive hypertrophic myocardiopathy caused by corticosteroid therapy for an infantile hemangioma. Unexpectedly, the propranolol caused regression of the infantile hemangioma as well. Another child who was treated with propranolol for increased cardiac output due to compression by an intracervical infantile hemangioma had reduction in the size of his infantile hemangioma after therapy began. Since then, case studies and small series of infantile hemangiomas treated successfully with propranolol or other bblocking agents have been reported. [11] [12] [13] [14] [15] [16] [17] Three different b-adrenergic receptor (AR) subtypes are known definitively to exist: b1, b2, and b3. These b-ARs are G-protein-coupled receptors and are present on endothelial cells. When b1 and b2-ARs are activated, they cause vasodilation of peripheral vessels, with b2 receptors predominating in most vascular smooth muscle, except for the coronary and cerebral arteries, where b1 receptors predominate. The b3 receptor is also identified in blood vessels as a mediator of vasodilation (reviewed in Guimaraes and Moura 18 ). Mechanistically, when activated, the receptors promote intracellular signal transduction pathways through the downstream activation of cyclic adenosine monophosphate (cAMP), and hence the activation of cAMP-dependent protein kinase A (PKA). The activation of PKA leads to activation of endothelial NO synthase (eNOS), releasing nitric oxide and causing vasodilation. In addition, activation of bARs results in the synthesis of proangiogenic factors, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), which activate proangiogenic cascades [extracellular signal-related kinases/mitogen-activated protein kinases (MAPK) cascade] promoting angiogenesis. [19] [20] [21] Also, activation of b-ARs inhibits apoptosis mediated by Src tyrosine kinase, MAPK, and caspase cascades. 20 PKA can phosphorylate b1 and b2-ARs, resulting in uncoupling and internalization. 22 Dephosphorylation ensues, followed by recycling of the receptor to the cell membrane. Phosphorylation and internalization leads to desensitization. The b3-AR is resistant to this desensitization. In addition to this difference, the b3-AR is not blocked by the b1-and b2-receptor antagonist propranolol. 23, 24 Propranolol, a nonselective b-AR antagonist, has been hypothesized to treat infantile hemangiomas via vasoconstriction, inhibition of angiogenesis, and induction of apoptosis. 20 Propranolol-induced vasoconstriction is thought to be mediated through inhibition of eNOS and NO release, resulting in the change in color and palpable softening seen in infantile hemangiomas with the onset of propranolol treatment. 20 In a prior report, we identified the immunohistochemical expression of b2-AR (B2-AR) and its phosphorylated form (B2-ARP) in a case of infantile hemangioma responding to propranolol treatment. 17 The B2-AR demonstrated cytoplasmic staining within the endothelial cells and arteriole smooth muscle. B2-ARP demonstrated granular cytoplasmic staining, potentially representing endocytosed phosphorylated B2-AR. In this current study, we determine the expression of the B2-AR, B2-ARP, and the b3-AR (B3-AR) in a series of various vascular tumors on a tissue microarray, including several infantile hemangiomas in different phases of growth and involution.
Materials and methods

Tissue Microarray
The vascular tumor tissue microarray (TA 185) contained a total of 304, 0.6 mm cores from formalin-fixed paraffin-embedded tissue, with each lesion represented in duplicate. Controls included breast ductal carcinoma, lymphoma, melanoma, skin, and placental tissue. Hematoxylin and eosin staining was used to confirm the classification of all vascular lesions according to the International Society for the Study of Vascular Anomalies. 25 Overall, the microarray contained 141 lesions: angiosarcoma (47), epithelioid hemangioendothelioma (15), lymphatic vascular malformation (8) , venous vascular malformation (7), littoral cell angioma (7), Kaposi sarcoma (5), intimal sarcoma (5), glomus tumor (5), spindle cell hemangioma (5), infantile hemangioma (5), epithelioid hemangioma (4), kaposiform hemangioendothelioma (4), intramuscular vascular malformation (4), hemangiopericytoma (3), arteriovenous vascular malformation (3), pyogenic granuloma (2), Masson's (2), bone hemangioma (2), and one case each of bone hemangioendothelioma, hobnail hemangioendothelioma, retiform hemangioendothelioma, synovial hemangioma, mixed small and large vessel vascular malformation, vascular malformation not otherwise specified, reactive vascular proliferation, and lymphangioleiomyomatosis.
Immunohistochemical Staining
Serial sections of 4 mm were cut from the tissue microarray block and used for immunohistochemical analysis. Expression of three b-ARs: B2-AR, B2-ARP, and B3-AR were evaluated for each lesion. The primary antibodies used were B2-AR (b2-Adrenergic Receptor antibody, Abcam, Cambridge, MA, USA; ab13300, rabbit polyclonal, 1:200 dilution, citrateinduced antigen retrieval), B2-ARP (b2-Adrenergic Receptor (phospho S346) antibody, Abcam;, ab62464, rabbit polyclonal, 1:200 dilution, citrateinduced antigen retrieval), and B3-AR (b3-Adrenergic Receptor antibody, Abcam, ab76249, 1:50 dilution, citrate-induced antigen retrieval). GLUT-1 immunohistochemical staining (GLUT1 antibody, Cell Marque, Rocklin, CA, USA; cat no. 355A-16, 1:300 dilution, citrate-induced antigen retrieval, pH 6.0) was used to confirm the diagnosis of the infantile hemangioma cores. The b-AR immunohistochemical reactions were visualized using the EnVision TM þ system (DAKO, Carpinteria, CA, USA) with diaminobenzidine (DAB) as the substrate buffer and chromogen. The GLUT1 immunohistochemical reaction was performed on the Leica Bond Max (Bannock Burn, IL, USA) using the Bond Polymer Refine Detection system with the DAB chromogen. The intensity of endothelial cell expression was interpreted by histopathological evaluation by the primary authors (KMC and AHM), using the following criteria: 0 ¼ negative; 1 ¼ equivocal/uninterpretable; 2 ¼ weak positive; 3 ¼ strong positive. Negative scores were given to cores with o5% staining, weak-positive scores were given to cores with staining in o50% of the lesional cells, and strong-positive scores were given to cores with staining in 450% of the lesional cells. In general, intensity highly correlated with percent staining b-Adrenergic receptor expression KM Chisholm et al with lesions: lesions with strong staining intensity stained 450% of endothelial cells, whereas lesions with weaker stain intensity stained o50% of cells. For each lesion, scores of 1 were eliminated, and the higher of the remaining scores used for analysis.
Results
Immunohistochemical Scoring
We utilized a three-tiered scale for scoring expression of B2-AR, B2-ARP, and B3-AR on the vascular tumor tissue microarray, with no staining (score 0), weakly positive staining (score 2), and strongly positive staining (score 3). Uninterpretable or equivocal stains (score 1) were also noted, and were usually due to missing cores or cores not being representative of the lesion. A total of 141 vascular lesions were represented in duplicate on the microarray. Of these 141 lesions, 80.9% (114/141) had an interpretable (score 0, 2, or 3) B2-AR stain, 90.1% (127/141) B2-ARP stain, and 74.5% (105/141) B3-AR stain.
Infantile Hemangioma Staining
Five lesions on the tissue microarray were confirmed by GLUT-1 staining (data not shown) to be infantile hemangiomas: one in the proliferative phase, one in the late proliferative/early involutional phase, and three in the involutional stage. As shown in Figure 1 , B2-AR and B3-AR stains were strongly positive in all three phases of infantile hemangiomas. The B2-ARP stain was strongly positive in the later phases of the infantile hemangiomas, but only weakly positive in the earlier proliferative phase.
Vascular Lesion Staining
A total of 125 other vascular lesions on the tissue microarray had at least one interpretable immunohistochemically stained core. Figure 2 displays examples of b-AR staining in five different vascular lesions. Table 1 records the number of lesions with interpretable staining for each b-AR and the percent of lesions that had strongly positive staining. As listed, strong expression of B2-AR was observed in multiple lesions, including all spindle cell hemangiomas, intimal sarcomas, various vascular malformations, as well as the majority of Kaposi sarcoma cases. Strong expression of B2-ARP was present in all cases of epithelioid hemangiomas, and in most epithelioid hemangioendotheliomas, kaposiform hemangioendotheliomas, littoral cell angiomas, and vascular malformations. Strong expression of B3-AR was present in the single cases of bone hemangioma, Figure 1 b-Adrenergic receptor (AR) staining in infantile hemangiomas. Hematoxylin and eosin staining of three different phases of infantile hemangioma: proliferative phase, late proliferative/early involutional phase, and involuted phase was performed, followed by immunohistochemical evaluation with b2-AR (B2-AR), its phosphorylated form (B2-ARP), and b3AR (B3-AR). As shown, B2-AR and B3-AR, each had strong ( þ þ ) expression in all phases, whereas B2-ARP had weak expression in the proliferation phase ( þ ), and strong expression in the later two phases. Strong expression of B2-AR and B2-ARP were not necessarily congruent, but weak expression of the counterpart was usually present. Hematoxylin and eosin staining of cases of epithelioid hemangioma, kaposiform hemangioendothelioma, glomus tumor, lymphatic vascular malformation, and venous vascular malformation was performed, followed by immunohistochemical evaluation with b2-AR (B2-AR), its phosphorylated form (B2-ARP), and b3-AR (B3-AR). As shown, epithelioid hemangioma had strong ( þ þ ) expression of B2-AR and B2-ARP, and weak ( þ ) expression of B3-AR. Kaposiform hemangioendothelioma had strong expression of B2-ARP and weak expression of both B2-AR and B3-AR. Glomus tumor lacked expression of all three receptors. Lymphatic vascular malformation had strong expression of B2-ARP, and weak expression of B2-AR and B3-AR. Last, venous vascular malformation had weak expression of all three receptors.
b-Adrenergic receptor expression
Discussion
This study is the first to report b-AR expression in a variety of vascular lesions, including infantile hemangiomas. Proangiogenic factors, such as the VEGF and bFGF are abundant in the proliferative phase of infantile hemangioma, 26 causing a proliferation of endothelial cells. As shown in this study, B2-AR and B3-AR are both strongly expressed in the (early) proliferative phase of infantile hemangioma, whereas B2-ARP is only weakly expressed. The significance of this observation is unclear, but may be related to the proliferative activity of the lesion, or availability of PKA in the early proliferative phase of infantile hemangiomas compared with the early involutional phase.
The success of propranolol therapy for infantile hemangiomas has lead to consideration of other vascular lesions for treatment. Kaposiform hemangioendotheliomas are aggressive vascular tumors with a high mortality rate, and only variably successful therapeutic strategies. Though only 67% of kaposiform hemangioendotheliomas expressed B2-AR in this study, Herman et al 27 recently reported a 6-year-old child with kaposiform hemangioendothelioma and Kasabach-Merritt syndrome, who was treated with propranolol and 4 weeks of vincristine (compared with the average of 22 weeks of vincristine), resulting in remission for over a year. In addition, propranolol has recently been reported to induce resolution of an aggressive, recurring orbital epithelioid hemangioma. 28 These examples illustrates that propranolol may be an important single or adjunctive therapy in many vascular lesions.
Though immunohistochemical studies demonstrate B2-AR staining in many lesions, this expression does not indicate that the lesions are responsive to b2-receptor antagonists. In this study, 50% of pyogenic granulomas had strong expression of B2-AR. Anecdotally, a patient with a diagnosis of infantile hemangioma was treated with propranolol. This individual failed treatment, and on pathology review, the lesion was found to be a pyogenic granuloma, not an infantile hemangioma. 29 However, b-AR expression was not determined in this case, so it is not known whether the pyogenic granuloma did not respond to propranolol due to lack of receptor expression.
We demonstrated variable b-AR expression in a broad spectrum of vascular lesions. Hence, propranolol or b3-receptor antagonists may be of benefit in some of the lesions. b2-receptor antagonists such as propranolol could affect apoptosis and decrease the responsiveness to VEGF. Even if they do not completely cure some lesions, b2-or b3-receptor antagonists may be able to stop growth or shrink certain lesions, and thereby facilitate surgical resection or other ablative methods. A large clinical trial of vascular tumors would be necessary to determine the significance of immunohistochemical expression of b-ARs as a biomarker predicting response to propranolol. Such a trial would allow reproducible, quantitative thresholds to be set similar to those used for epidermal growth factor receptor expression in lung cancer therapy. Vascular malformation, not otherwise specified b-Adrenergic receptor expression
